WO2001089281A3 - Tumorassoziiertes antigen (b132), charakterisiert durch seq. id. no. 2 - Google Patents

Tumorassoziiertes antigen (b132), charakterisiert durch seq. id. no. 2 Download PDF

Info

Publication number
WO2001089281A3
WO2001089281A3 PCT/EP2001/005787 EP0105787W WO0189281A3 WO 2001089281 A3 WO2001089281 A3 WO 2001089281A3 EP 0105787 W EP0105787 W EP 0105787W WO 0189281 A3 WO0189281 A3 WO 0189281A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
associated antigen
seq
relates
chemotherapeutical
Prior art date
Application number
PCT/EP2001/005787
Other languages
English (en)
French (fr)
Other versions
WO2001089281A2 (de
Inventor
Guenther Adolf
Karl-Heinz Heider
Ulrich Koenig
Wolfgang Sommergruber
Agnes Gruenfelder
Roger Abseher
Original Assignee
Boehringer Ingelheim Int
Guenther Adolf
Karl-Heinz Heider
Ulrich Koenig
Wolfgang Sommergruber
Agnes Gruenfelder
Roger Abseher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Guenther Adolf, Karl-Heinz Heider, Ulrich Koenig, Wolfgang Sommergruber, Agnes Gruenfelder, Roger Abseher filed Critical Boehringer Ingelheim Int
Priority to EP01945170A priority Critical patent/EP1297009A2/de
Publication of WO2001089281A2 publication Critical patent/WO2001089281A2/de
Publication of WO2001089281A3 publication Critical patent/WO2001089281A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Tumorassoziiertes Antigen B132, davon abgeleitete immunogene Peptide und dafür kodierende DNA-Moleküle sowie deren Verwendung in der Immuntherapie von Krebserkrankungen sowie als Zielmolekül für die chemotherapeutische Intervention.
PCT/EP2001/005787 2000-05-23 2001-05-21 Tumorassoziiertes antigen (b132), charakterisiert durch seq. id. no. 2 WO2001089281A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01945170A EP1297009A2 (de) 2000-05-23 2001-05-21 Tumor-assoziiertes antigen b132

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10025521A DE10025521A1 (de) 2000-05-23 2000-05-23 Tumor-assoziiertes Antigen B132
DE10025521.3 2000-05-23

Publications (2)

Publication Number Publication Date
WO2001089281A2 WO2001089281A2 (de) 2001-11-29
WO2001089281A3 true WO2001089281A3 (de) 2002-06-20

Family

ID=7643261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005787 WO2001089281A2 (de) 2000-05-23 2001-05-21 Tumorassoziiertes antigen (b132), charakterisiert durch seq. id. no. 2

Country Status (3)

Country Link
EP (1) EP1297009A2 (de)
DE (1) DE10025521A1 (de)
WO (1) WO2001089281A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313617C (zh) 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006723A1 (en) * 1998-07-30 2000-02-10 Yeda Research And Development Company Ltd At The Weizmann Institute Of Science Tumor associated antigen peptides and use of same as anti-tumor vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329053A1 (en) * 1998-05-28 1999-12-02 Incyte Pharmaceuticals, Inc. Human socs proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006723A1 (en) * 1998-07-30 2000-02-10 Yeda Research And Development Company Ltd At The Weizmann Institute Of Science Tumor associated antigen peptides and use of same as anti-tumor vaccines

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL NCBI; 27 January 2000 (2000-01-27), ANSORGE W. ET AL.: "Homo sapiens mRNA; partial cds", XP002177422 *
DIATCHENKO L ET AL: "SUPPRESSION SUBTRACTIVE HYBRIDIZATION: A METHOD FOR GENERATING DIFFERENTIALLY REGULATED OR TISSUE-SPECIFIC CDNA PROBES AND LIBRARIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, 1 June 1996 (1996-06-01), pages 6025 - 6030, XP002911922, ISSN: 0027-8424 *
PETERSEN SIMONE ET AL: "Gene expression profiling of advanced lung cancer", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 86, no. 4, 15 May 2000 (2000-05-15), pages 512 - 517, XP002166298, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
DE10025521A1 (de) 2001-12-06
WO2001089281A2 (de) 2001-11-29
EP1297009A2 (de) 2003-04-02

Similar Documents

Publication Publication Date Title
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
CA2266319A1 (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
WO1996040039A3 (en) Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
AU2003296330A1 (en) Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
WO2002008426A3 (en) Fh-binding protein of streptococcus pneumoniae
EP1536006A4 (de) Krebsantigene und deren nutzung
WO2005019435A8 (en) Anti-cancer vaccines
WO2001083739A3 (en) Human pellino polypeptides
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
WO2001089281A3 (de) Tumorassoziiertes antigen (b132), charakterisiert durch seq. id. no. 2
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
WO2005039495A3 (en) Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
CO5280140A1 (es) Antigeno (c42) asociado a tumores
WO2009083968A8 (en) Novel protein
AU5992500A (en) Compound derived from an offset orf of the ice gene
WO2002007740A3 (de) Schlangentoxin und dessen verwendung als arzneimittel
WO2004003009A3 (en) Francisella tularensis immunogenic proteins and dna encoding these
WO1999031256A3 (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
AU2001227570A1 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2002000822A3 (fr) Nouveau polypeptide, sous-unite humaine 2 $g(b) 16.5 du facteur d'initiation necessaire a la synthese proteique, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2001945170

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001945170

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001945170

Country of ref document: EP